Cocrystal Pharma Appoints Antiviral Drug Development Veteran Carol Brosgart, MD to Board of Directors
核心洞察
Cocrystal Pharma appointed Carol Brosgart, MD to its Board of Directors, effective August 12, 2026, bringing decades of antiviral therapy and epidemiology expertise.
Dr. Brosgart contributed to the development and FDA approval of Gilead's antiviral therapies Viread and Hepsera during more than a decade at the company.
Her clinical and scientific insights will support advancement of CDI-988 for norovirus (搜索) and the broader antiviral pipeline, according to Chairman Roger Kornberg.
Cocrystal Pharma, Inc. (Nasdaq: COCP), a clinical-stage biotechnology company developing novel antiviral therapeutics, announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory to the Bothell, Washington-based company.
"Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide," said Roger Kornberg, Ph.D., Chairman of the Board, Chief Scientist, and Chairman of the Scientific Advisory Board at Cocrystal and Nobel laureate. "Her clinical and scientific insights will be invaluable as we work to advance the clinical development of CDI-988 for norovirus (搜索), as well as the broader development of our antiviral pipeline."
James Sapirstein, Chief Executive Officer of Cocrystal Pharma, added, "I've had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn't be more pleased to have her insight guiding Cocrystal at this pivotal stage."
A Distinguished Career in Antiviral Development
Dr. Brosgart has extensive experience in government service and biopharmaceutical consulting, and has served on the boards of numerous biotechnology companies. She was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She is a member of the Board of Directors of the Hepatitis B Foundation, previously co-chaired the National Task Force on Hepatitis B, and served as a Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and the Viral Hepatitis Action Coalition at the CDC Foundation.
Dr. Brosgart currently sits on the Boards of Directors of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, and previously held board positions at Abivax, Mirum Pharmaceuticals, Tobira Therapeutics, and Juvaris. She spent more than a decade at Gilead Sciences, where she played a critical role in the development and regulatory approval of the antiviral therapies Viread and Hepsera. She received her M.D. from the University of California, San Francisco (UCSF) School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.
Advancing a Structure-Based Antiviral Pipeline
Cocrystal Pharma is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2 (搜索)), and hepatitis C (搜索) viruses. The Company employs unique structure-based technologies to create viable antiviral drugs.
The Company's structure-based drug discovery platform technology is designed to create next-generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, Cocrystal's compounds aim to maintain potency against mutating strains while minimizing off-target effects, offering potentially safer, broad-spectrum antiviral solutions. The platform provides a three-dimensional structure of inhibitor complexes at near-atomic resolution, enabling rapid turnaround of structural information through highly automated X-ray data processing and refinement.
Dr. Brosgart's appointment follows Cocrystal's June 2026 appointment of James Sapirstein as Chief Executive Officer, a biopharma industry leader who has participated in or led 23 product launches and previously served as CEO of Contravir Pharmaceuticals and founding CEO of Tobira Therapeutics.